Mehmet Fatih Yetkin
Overview
Explore the profile of Mehmet Fatih Yetkin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
61
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Taskiran E, Terzi M, Helvaci E, Eser M, Avci B, Faruk T, et al.
Mult Scler Relat Disord
. 2025 Feb;
95:106307.
PMID: 39921990
No abstract available.
2.
Mutlu M, Karakaya T, Celebi H, Duymus F, Seyhan S, Yilmaz S, et al.
Clin Genet
. 2024 Oct;
107(2):188-195.
PMID: 39435674
Genomic repeat sequences are patterns of nucleic acids that exist in multiple copies throughout the genome. More than 60 Mendelian disorders are caused by the expansion or contraction of these...
3.
Atmaca M, Bulbul N, Ates M, Selbest B, Eren F, Guler S, et al.
Noro Psikiyatr Ars
. 2024 Sep;
67(3):241-247.
PMID: 39258124
Introduction: Acute ischemic stroke (AIS) is a devastating complication of COVID-19 with high morbidity and mortality. In this study, we reported the frequency, characteristics, and outcome of AIS in patients...
4.
Tunc A, Yetkin M, Seferoglu M, Inanc Y, Sivaci A, Turkoglu S, et al.
Mult Scler Relat Disord
. 2024 Jul;
88():105757.
PMID: 38972107
Background: This study investigates the gap in understanding the dynamics of recurring disease activity (RDA) in RRMS patients after fingolimod (FGL) treatment discontinuation. The aim is to investigate RDA in...
5.
Lal A, Foong Y, Sanfilippo P, Spelman T, Rath L, Levitz D, et al.
J Neurol
. 2024 Jun;
271(9):5813-5824.
PMID: 38935148
Background: The COVID-19 pandemic raised concern amongst clinicians that disease-modifying therapies (DMT), particularly anti-CD20 monoclonal antibodies (mAb) and fingolimod, could worsen COVID-19 in people with multiple sclerosis (pwMS). This study...
6.
Koc S, Sen S, Terzi Y, Kizilay F, Demir S, Bekar Aksoy D, et al.
Balkan Med J
. 2024 Jun;
41(4):272-279.
PMID: 38828767
Background: Optic neuritis, myelitis, and neuromyelitis optica spectrum disorder (NMOSD) have been associated with antibodies against myelin oligodendrocyte glycoprotein-immunoglobulin G (anti-MOG-IgG). Furthermore, patients with radiological and demographic features atypical for...
7.
Yetkin N, Yetkin M, Ketencioglu B, Oymak F, Gulmez I, Yilmaz I, et al.
Turk J Med Sci
. 2024 May;
53(5):1301-1311.
PMID: 38812999
Background/aim: It is known that the correlation of pulmonary function tests (PFT) with muscle dysfunction is insufficient. Here, we aimed to evaluate the diaphragm functions in individuals with Friedreich's ataxia...
8.
Taskiran E, Terzi M, Helvaci E, Eser M, Avci B, Faruk T, et al.
Mult Scler Relat Disord
. 2024 Feb;
83:105391.
PMID: 38335838
Background/aim: Multiple sclerosis (MS) is an inflammatory demyelinating central nervous system (CNS) disease. Among the paraclinical tests, brain and spinal Magnetic Resonance Imaging (MRI) is primarily involved in the diagnosis...
9.
Terzi M, Helvaci E, Sen S, Boz C, Cilingir V, Akcali A, et al.
Noro Psikiyatr Ars
. 2023 Jun;
60(2):190.
PMID: 37287556
[This corrects the article on p. 23 in vol. 60, PMID: 36911568.].
10.
Terzi M, Helvaci E, Sen S, Boz C, Cilingir V, Akcali A, et al.
Noro Psikiyatr Ars
. 2023 Mar;
60(1):23-27.
PMID: 36911568
Introduction: Fingolimod is the first oral immunomodulatory treatment used as secondary care therapy in the treatment of multiple sclerosis for the last 10 years. The objective of our study is...